Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus

Trial Profile

Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Anakinra (Primary) ; Etanercept (Primary) ; Liraglutide (Primary) ; Plerixafor (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top